Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
NEW YORK, May 09, 2017 -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its second fiscal quarter ended March 31, 2017 after the market close on Thursday, May 11, 2017. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.
| Conference Call & Webcast | |
| Thursday, May 11, 2017 at 5:00pm Eastern Time | |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13661723 |
| Webcast: | http://public.viavid.com/index.php?id=124321 |
| Replays – Available through May 25, 2017 | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 13661723 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
